**PATENT** 

**DOCKET NO.: 3DP-0418(1030002)** 

DIFE 1.9' AND SO

### N THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re Application of: LU, et al.

Confirmation No.: 2206

JAN 0 6 2004

**Application No.: 10/058,215** 

Group Art Unit: 1624

**F**011 0=---

Filing Date: January 29, 2002

Examiner: Habte, Kahsay

TECH CENTER 1600/2900

For: Substituted Indoles And Their Use As Integrin Antagonists

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# STATEMENT IN SUPPORT OF PETITION TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.48(a)

I, Bruce E. Tomczuk, state that:

- 1. An error in inventorship exists in the above-identified patent application.
- 2. I understand that, to correct this error, I am being added as an inventor.
- 3. This error in inventorship occurred without deceptive intention on my part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this statement is directed.

Date:  $\frac{12/11/03}{}$ 

BRUCE E. TOMCZUK<sup>\</sup>

© 2002 WW

12-22-03

DOCKET NO.: 3DP-0418(1030002)

**PATENT** 



41

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: LU, et al.

Confirmation No.: 2206

**Application No.: 10/058,215** 

Group Art Unit: 1624

Filing Date: January 29, 2002

Examiner: Habte, Kahsay

RECEIVED

For: Substituted Indoles And Their Use As Integrin Antagonists

JAN 0 6 2004

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450 TECH CENTER 1600/2900

## CONSENT OF ASSIGNEE TO CHANGE OF INVENTORSHIP IN PATENT APPLICATION PURSUANT TO 1.48(a)(5) OR (c)(5)

3-Dimensional Pharmaceuticals, Inc., owner by assignment of the above patent application						
	in the assignment being recorded concurrently herewith					
$\boxtimes$	in the assignment recorded in the PTO on May 20, 2002.					
	Reel 012913 Frame 0369					
hereby consents to the amendment of the inventorship of this patent application as requested						
$\boxtimes$	in the Request For Correction Of Inventorship Of Patent Application					
	in the papers mailed to the PTO on .					
A Statement Under 37 CFR §3.73(b) is attached.						

3-DIMENSIONAL PHARMACEUTICALS, INC.

Date: 12-2-03

Name: Mary A. Appollina Title: Assistant Secretary

### STATEMENT UNDER 37 CFR § 3.73(b)

3-Dime	ensiona	l Pharmaceuticals, Inc	c., a corpora	ation of Delaware	•				
states t	hat it is	:		-					
$\boxtimes$	the assignee of the entire right, title, and interest; or								
	an assi	ssignee of an undivided part interest							
in the patent application/patent identified above by virtue of either:									
A. An assignment from the inventor(s) of the patent application/patent identified above.									
	∑ 1. The assignment was recorded in the Patent and Trademark Office at Recorded 12913, Frame(s) 0369.								
	2. The assignment has not yet been recorded. A copy of the assignment i attached.								
OR  B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:									
	i.	From: Trademark Office at is attached.	To: Reel	The document w, Frame(s)	vas recorded in th , or for which a				
	ii.	From: Trademark Office at is attached.	To: Reel	The document w, Frame(s)	vas recorded in the , or for which a				
	iii.	From: Trademark Office at is attached.	To: Reel	The document w, Frame(s)	vas recorded in the , or for which a				
	Additional documents in the chain of title are listed on a supplemental sheet.								

DOCKET NO.: 3DP-0418(1030002) - 3 - PATENT

Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

3-DIMENSIONAL PHARMACEUTICALS, INC.

Date: 12-9-03

Name: Mary A. Appollina Title: Assistant Secretary **DOCKET NO.: 3DP-0418(103002) PATENT** 



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re Application of: LU, et al.

Confirmation No.: 2206

JAN n 6 2004

**Application No.: 10/058,215** 

Group Art Unit: 1624

Filing Date: January 29, 2002

Examiner: Habte, Kahsay

**TECH CENTER 1600/2900** 

For: Substituted Indoles And Their Use As Integrin Antagonists

EXPRESS MAIL LABEL NO: EL 969189654 US **DATE OF DEPOSIT: December 19, 2003** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT, REQUEST AND PROCESSING FEE TO DELETE AND/OR ADD TO ORIGINAL ERRONEOUSLY NAMED OR NOT NAMED INVENTOR(S) IN DECLARATION - NONPROVISIONAL APPLICATION -(37 CFR § 1.48(a))

This amendment and request is to correct the incorrect original naming of inventor(s) in the declaration under 37 CFR § 1.48(a) as set forth and filed on May 20, 2002.

Addition and/or Deletion of Inventor(s)

Add the following previously unnamed person(s) as inventor(s) of this  $\boxtimes$ application:

Bruce E. Tomczuk

Delete the following previously incorrectly named inventor(s)

Attachments

Attached is

A statement from

(check items that apply)

12/31/2003 AWUNDAF1 00000014 10058215

01 FC:1460

130.00 OP

**DOCKET NO.: 3DP-0418(1030002)** - 2 -**PATENT** each person being added as an inventor that the error in 冈 inventorship occurred without deceptive intention on his or her part. 37 CFR § 1.48(a)(1). each person being deleted as an inventor that the error in  $\Box$ inventorship occurred without deceptive intention on his or her part. 37 CFR § 1.48(a)(1). a declaration by each of the actual inventor(s) as required by 37 CFR §  $\boxtimes$ 1.63 (or as permitted by  $\S\S\S$  1.42, 1.43, or 1.47. 37 CFR  $\S$  1.48(a)(2)). written assent of the assignee (if any of the original inventors executed  $\bowtie$ an assignment). 37 CFR § 1.48(a)(4). Processing Fee Payment (37 CFR § 1.17(i))  $\boxtimes$ A check in the amount of \$130.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. Please charge Deposit Account No. 23-3050 in the amount of \$  $\Box$ This sheet is attached in duplicate. The Commission is hereby authorized to charge payment of the above fees  $\boxtimes$ associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in duplicate. Date: December 19, 2003 Registration No. 45,873

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2003 WW